267 related articles for article (PubMed ID: 31973751)
1. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review.
Petersen LJ; Zacho HD
Cancer Imaging; 2020 Jan; 20(1):10. PubMed ID: 31973751
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
3. Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer.
Hinsenveld FJ; Wit EMK; van Leeuwen PJ; Brouwer OR; Donswijk ML; Tillier CN; Vegt E; van Muilekom E; van Oosterom MN; van Leeuwen FWB; van der Poel HG
J Nucl Med; 2020 Apr; 61(4):540-545. PubMed ID: 31562222
[TBL] [Abstract][Full Text] [Related]
4. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A
Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770
[TBL] [Abstract][Full Text] [Related]
5. 18 F-prostate specific membrane antigen positron emission tomography/computerized tomography for lymph node staging in medium/high risk prostate cancer: A systematic review and meta-analysis.
Lv Z; Song L; Wang M; Hou H; Li H; Wang X; Wang J; Wang J; Liu M
Chin Med J (Engl); 2024 Apr; 137(8):949-958. PubMed ID: 37690993
[TBL] [Abstract][Full Text] [Related]
6.
Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
[TBL] [Abstract][Full Text] [Related]
7.
Petersen LJ; Nielsen JB; Langkilde NC; Petersen A; Afshar-Oromieh A; De Souza NM; De Paepe K; Fisker RV; Arp DT; Carl J; Haberkorn U; Zacho HD
World J Urol; 2020 Apr; 38(4):939-948. PubMed ID: 31190153
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.
Maurer T; Gschwend JE; Rauscher I; Souvatzoglou M; Haller B; Weirich G; Wester HJ; Heck M; Kübler H; Beer AJ; Schwaiger M; Eiber M
J Urol; 2016 May; 195(5):1436-1443. PubMed ID: 26682756
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Accuracy of
Cantiello F; Gangemi V; Cascini GL; Calabria F; Moschini M; Ferro M; Musi G; Butticè S; Salonia A; Briganti A; Damiano R
Urology; 2017 Aug; 106():139-145. PubMed ID: 28438628
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
[No Abstract] [Full Text] [Related]
12. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
Kim SJ; Lee SW; Ha HK
Urol Int; 2019; 102(1):27-36. PubMed ID: 30269140
[TBL] [Abstract][Full Text] [Related]
13. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.
Hermsen R; Wedick EBC; Vinken MJM; van Kalmthout LWM; Küsters-Vandevelde HVN; Wijers CHW; Somford DM; van Basten JA
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3929-3937. PubMed ID: 35543733
[TBL] [Abstract][Full Text] [Related]
14. Gallium-68-prostate-specific membrane antigen (
van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
[TBL] [Abstract][Full Text] [Related]
15. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer.
Koschel S; Murphy DG; Hofman MS; Wong LM
Curr Opin Urol; 2019 Nov; 29(6):569-577. PubMed ID: 31567440
[TBL] [Abstract][Full Text] [Related]
16. PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management.
Haxhimolla J; Kua B; Gilbourd D; Haxhimolla H
Semin Oncol Nurs; 2020 Aug; 36(4):151044. PubMed ID: 32723519
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification and staging in prostate cancer with prostatic specific membrane antigen PET/CTObjective: A one-stop-shop.
Gupta M; Choudhury PS; Rawal S; Goel HC; Singh A; Talwar V; Sahoo SK
Hell J Nucl Med; 2017; 20 Suppl():156. PubMed ID: 29324926
[TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of
Malaspina S; Anttinen M; Taimen P; Jambor I; Sandell M; Rinta-Kiikka I; Kajander S; Schildt J; Saukko E; Noponen T; Saunavaara J; Dean PB; Sequeiros RB; Aronen HJ; Kemppainen J; Seppänen M; Boström PJ; Ettala O
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2951-2959. PubMed ID: 33715033
[TBL] [Abstract][Full Text] [Related]
20. Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.
Domachevsky L; Bernstine H; Goldberg N; Nidam M; Catalano OA; Groshar D
Eur Radiol; 2020 Jan; 30(1):328-336. PubMed ID: 31332559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
